Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

• Conditions: Portal Vein, Cavernous Transformation Of
• Interventions: Drug: Montelukast

• Registration Number: NCT02505113
• Lead Sponsor: Sun Yat-sen University

Brief Summary

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

Detailed Description

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.

Study Timeline

• Study Start: 2010-10
• Study First Submitted: 2015-07-16
• Study First Submitted QC: 2015-07-20
• Study First Posted: 2015-07-22
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-28
• Last Update Posted: 2015-10-29
• Primary Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• All patients with CTPV.

Exclusion Criteria

• Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
CTPV treated with Montelukast	Montelukast	Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).

Primary Outcome Measures

Name	Time	Method
Ascites Volume (mL)	6 month	Ascites measured by CT scanning or ultrasound (If the patients had the history of ascites before)
Hydrothorax Volume (mL)	6 month	Hydrothorax measured by CT scanning or ultrasound (If the patients had the history of hydrothorax before)

Trial Locations

Locations (1)

Department of Radiology; 🇨🇳 Guangzhou, Guangdong, China